$MNTS
Momentus Inc. Stock $mnts

$mnts Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000178116224000009 Filed on October 15, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023 Q1
Revenue	$500.0K	$1.023M	$22.00K
YoY Change	2172.73%	752.5%
Cost Of Revenue		$348.0K
YoY Change
Gross Profit	$513.0K	$675.0K	$22.00K
YoY Change	2231.82%	462.5%
Gross Profit Margin	102.6%	65.98%	100.0%
Selling, General & Admin	$6.164M	$6.484M	$10.27M
YoY Change	-39.98%	-40.67%	-30.86%
% of Gross Profit	1201.56%	960.59%	46681.82%
Research & Development	$2.676M	$8.036M	$10.12M
YoY Change	-73.55%	-21.85%	1.48%
% of Gross Profit	521.64%	1190.52%	45995.45%
Depreciation & Amortization	$200.0K	$227.0K	$200.0K
YoY Change	0.0%	-12.36%	-33.33%
% of Gross Profit	38.99%	33.63%	909.09%
Operating Expenses	$8.840M	$14.52M	$20.39M
YoY Change	-56.64%	-31.55%	-17.87%
Operating Profit	-$8.327M	-$13.85M	-$20.37M
YoY Change	-59.12%	-34.36%	-17.95%
Interest Expense	-$39.00K	-$58.00K	$920.0K
YoY Change	-104.24%	-90.44%	-38.34%
% of Operating Profit
Other Income/Expense, Net	$14.00K	-$198.0K	-$458.0K
YoY Change	-103.06%	-110.92%	-77.21%
Pretax Income	-$8.313M	-$14.10M	-$20.83M
YoY Change	-60.08%	-42.3%	-22.39%
Income Tax
% Of Pretax Income
Net Earnings	-$8.313M	-$14.10M	-$20.80M
YoY Change	-60.03%	-42.3%	-22.49%
Net Earnings / Revenue	-1662.6%	-1378.4%	-94545.45%
Basic Earnings Per Share	-$0.66		-$0.24
Diluted Earnings Per Share	-$0.66	-$2.30	-$0.24
COMMON SHARES
Basic Shares Outstanding	12.59M shares	6.562M shares	94.06M shares
Diluted Shares Outstanding	12.59M shares		87.56M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.672M	$2.118M	$38.63M
YoY Change	-95.67%	-96.53%	-71.51%
Cash & Equivalents	$1.700M	$2.100M	$38.60M
Short-Term Investments
Other Short-Term Assets	$7.224M	$8.513M	$10.40M
YoY Change	-30.56%	-23.86%	28.69%
Inventory
Prepaid Expenses
Receivables	$15.00K	$0.00
Other Receivables	$408.0K
Total Short-Term Assets	$9.319M	$10.73M	$53.03M
YoY Change	-82.43%	-85.93%	-63.09%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.045M	$3.252M	$3.844M
YoY Change	-20.79%	-19.02%	-18.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$584.0K	$602.0K	$4.670M
YoY Change	-87.49%	-87.22%	-18.78%
Total Long-Term Assets	$9.420M	$9.918M	$15.81M
YoY Change	-40.41%	-38.58%	-15.63%
TOTAL ASSETS
Total Short-Term Assets	$9.319M	$10.73M	$53.03M
Total Long-Term Assets	$9.420M	$9.918M	$15.81M
Total Assets	$18.74M	$20.65M	$68.84M
YoY Change	-72.78%	-77.66%	-57.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.831M	$2.805M	$2.092M
YoY Change	35.33%	25.28%	-36.39%
Accrued Expenses	$4.458M	$4.754M	$6.496M
YoY Change	-31.37%	-40.77%	-32.11%
Deferred Revenue	$495.0K	$0.00	$2.136M
YoY Change	-76.83%	-100.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$2.273M	$11.29M
YoY Change	-100.0%	-80.45%	19.7%
Total Short-Term Liabilities	$9.614M	$11.11M	$31.73M
YoY Change	-69.7%	-74.3%	-8.08%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$171.0K
YoY Change	-100.0%	-100.0%	-98.49%
Other Long-Term Liabilities	$496.0K	$489.0K	$471.0K
YoY Change	5.31%	5.16%	-3.48%
Total Long-Term Liabilities	$5.640M	$6.353M	$8.165M
YoY Change	-30.92%	-40.01%	-69.36%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.614M	$11.11M	$31.73M
Total Long-Term Liabilities	$5.640M	$6.353M	$8.165M
Total Liabilities	$15.25M	$17.46M	$39.90M
YoY Change	-61.77%	-67.55%	-34.78%
SHAREHOLDERS EQUITY
Retained Earnings	-$381.4M	-$373.0M	-$325.0M
YoY Change	17.35%	22.65%	37.99%
Common Stock			$1.000K
YoY Change			0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.485M	$3.187M	$28.95M
YoY Change
Total Liabilities & Shareholders Equity	$18.74M	$20.65M	$68.84M
YoY Change	-72.78%	-77.66%	-57.62%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023 Q1
OPERATING ACTIVITIES
Net Income	-$8.313M	-$14.10M	-$20.80M
YoY Change	-60.03%	-42.3%	-22.49%
Depreciation, Depletion And Amortization	$200.0K	$227.0K	$200.0K
YoY Change	0.0%	-12.36%	-33.33%
Cash From Operating Activities	-$5.300M	-$15.84M	-$18.70M
YoY Change	-71.66%	-3.37%	-18.91%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$12.00K	$43.00K
YoY Change	-100.0%	-89.92%	-85.17%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$39.00K	-$12.00K	-$52.00K
YoY Change	-25.0%	-86.96%	-90.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	-$8.000M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$4.849M	7.829M	-$3.793M
YoY Change	-227.84%	-339.42%	304.37%
NET CHANGE
Cash From Operating Activities	-$5.300M	-15.84M	-$18.70M
Cash From Investing Activities	-$39.00K	-12.00K	-$52.00K
Cash From Financing Activities	$4.849M	7.829M	-$3.793M
Net Change In Cash	-$443.0K	-8.022M	-$22.54M
YoY Change	-98.03%	-59.39%	-8.07%
FREE CASH FLOW
Cash From Operating Activities	-$5.300M	-$15.84M	-$18.70M
Capital Expenditures	$0.00	$12.00K	$43.00K
Free Cash Flow	-$5.300M	-$15.85M	-$18.74M
YoY Change	-71.72%	-4.0%	-19.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2676000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10119000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6164000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-8313000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	92000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-20825000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	28946000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2024Q1	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	408000	usd
CY2023Q4	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	100000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7224000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8513000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	9319000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	10731000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3045000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3252000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	347000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	341000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5067000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5350000	usd
CY2024Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	377000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	373000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	584000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	602000	usd
CY2024Q1	us-gaap	Assets Assets	18739000	usd
CY2023Q4	us-gaap	Assets Assets	20649000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2831000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-381360000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20649000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-373047000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	3485000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3187000	usd
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	384845000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	513000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	22000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2805000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4458000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4754000	usd
CY2024Q1	us-gaap	Loans Payable Current LoansPayableCurrent	0	usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent	2273000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	495000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1298000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1268000	usd
CY2024Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	526000	usd
CY2023Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	0	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	9614000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11109000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	618000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	998000	usd
CY2024Q1	mnts	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	3000	usd
CY2023Q4	mnts	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	3000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4523000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4863000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	496000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	489000	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5640000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6353000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	15254000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	17462000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10270000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	8840000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	20389000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8327000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-20367000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	112000	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	18000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	555000	usd
CY2024Q1	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	57000	usd
CY2023Q1	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	920000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	53000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	19000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	14000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-458000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-8313000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-20825000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.66
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-11.90
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-11.90
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12586953	shares
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12586953	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1750465	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1750465	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3187000	usd
CY2024Q1	mnts	Stock Issued During Period Value Section16 Officer Tax Coverage Exchange StockIssuedDuringPeriodValueSection16OfficerTaxCoverageExchange	3000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1443000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7171000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	3485000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	38607000	usd
CY2023Q1	mnts	Stock Issued During Period Value Section16 Officer Tax Coverage Exchange StockIssuedDuringPeriodValueSection16OfficerTaxCoverageExchange	60000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1720000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9300000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	112000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-8313000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-20825000	usd
CY2024Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	222000	usd
CY2023Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	229000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	46000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	492000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	283000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	267000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	112000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1443000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1720000	usd
CY2024Q1	mnts	Issuance Of Common Stock For Consulting Services IssuanceOfCommonStockForConsultingServices	0	usd
CY2023Q1	mnts	Issuance Of Common Stock For Consulting Services IssuanceOfCommonStockForConsultingServices	57000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	15000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1288000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-704000	usd
CY2024Q1	us-gaap	Increase Decrease In Insurance Settlements Receivable IncreaseDecreaseInInsuranceSettlementsReceivable	308000	usd
CY2023Q1	us-gaap	Increase Decrease In Insurance Settlements Receivable IncreaseDecreaseInInsuranceSettlementsReceivable	0	usd
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-18000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-41000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	26000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-211000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-276000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1538000	usd
CY2024Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	usd
CY2023Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	39000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-4000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	12000	usd
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	115000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	481000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-310000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-282000	usd
CY2024Q1	mnts	Increase Decrease In Litigation Settlement Contingency IncreaseDecreaseInLitigationSettlementContingency	526000	usd
CY2023Q1	mnts	Increase Decrease In Litigation Settlement Contingency IncreaseDecreaseInLitigationSettlementContingency	0	usd
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	6000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	6000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5253000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18696000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	43000	usd
CY2024Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	39000	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	9000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-39000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-52000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	92000	usd
CY2024Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	60000	usd
CY2024Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2319000	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	3102000	usd
CY2024Q1	mnts	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts	0	usd
CY2023Q1	mnts	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts	23000	usd
CY2024Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	10000000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8000000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10000000	usd
CY2024Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	829000	usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	700000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4849000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3793000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-443000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-22541000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2492000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62413000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2049000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39872000	usd
CY2024Q1	mnts	Purchases Of Intangibles Assets During Noncash Or Partial Noncash Transaction Included In Accounts Payable And Accrued Expenses PurchasesOfIntangiblesAssetsDuringNoncashOrPartialNoncashTransactionIncludedInAccountsPayableAndAccruedExpenses	1000	usd
CY2023Q1	mnts	Purchases Of Intangibles Assets During Noncash Or Partial Noncash Transaction Included In Accounts Payable And Accrued Expenses PurchasesOfIntangiblesAssetsDuringNoncashOrPartialNoncashTransactionIncludedInAccountsPayableAndAccruedExpenses	7000	usd
CY2024Q1	mnts	Deferred Offering Costs Incurred During Noncash Or Partial Noncash Transaction Included In Accounts Payable And Accrued Expenses DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransactionIncludedInAccountsPayableAndAccruedExpenses	0	usd
CY2023Q1	mnts	Deferred Offering Costs Incurred During Noncash Or Partial Noncash Transaction Included In Accounts Payable And Accrued Expenses DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransactionIncludedInAccountsPayableAndAccruedExpenses	64000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	12000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	389000	usd
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. Nature of Operations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Momentus Inc. (together with its consolidated subsidiaries “Momentus” or the “Company”) is a U.S. commercial space company that offers satellites, satellite buses, satellite technologies, and space infrastructure services, including in-space transportation, hosted payloads and in-orbit services. Momentus is making new ways of operating in space possible with its in-space transfer and service vehicles, powered by an innovative, space-proven water plasma-based propulsion system.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Momentus has launched four missions to date, deployed 17 customer satellites, and provided hosted payload services. Three of these missions involved operation of the Vigoride OSV in orbit. During these three Vigoride missions, the system and technology were tested repeatedly. Improvements based on lessons learned during these missions were rapidly incorporated. As a result of these three missions, the Vigoride OSV has been successfully demonstrated in space and accumulated significant flight heritage. The Company has produced its next Orbital Service Vehicle, Vigoride 7, that it intends to utilize on a future mission or for use as a satellite bus. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Vigoride Orbital Service Vehicle, Momentus is now also offering its M-1000 satellite bus which has substantial commonality with Vigoride. With a growing demand for satellite bus services, Momentus is positioned to advance its hardware and flight-proven technology for this market. The M-1000 bus is a flexible option to meet various mission requirements. Innovations to improve sensor capability, maneuverability, increased power, and lower costs are integrated into the product. Momentus believes it can manufacture satellite buses like the M-1000 at a rapid and scalable pace. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Momentus has completed work in support of its Small Business Innovation Research contract from the Space Development Agency that was signed in August 2023. This project's scope involved making tailored modifications to the system underlying the M-1000 satellite bus and Vigoride OSV to support a full range of U.S. Department of Defense (DoD) payloads. Some of these areas include adding a secure payload interface, optical communications terminals, a high-volume data recorder, and improving the modularity of the propulsion system.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combination</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 12, 2021, the Company consummated a merger pursuant to the terms of the Agreement and Plan of Merger, dated October 7, 2020, and as amended on March 5, 2021, April 6, 2021, and June 29, 2021 (the “Merger Agreement”), by and among Stable Road Acquisition Corp (“SRAC”), Project Marvel First Merger Sub, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of SRAC (“First Merger Sub”), and Project Marvel Second Merger Sub, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of SRAC (“Second Merger Sub”), pursuant to which First Merger Sub merged with and into Momentus Inc., a Delaware corporation (“Legacy Momentus”) with Legacy Momentus as the surviving corporation of the First Merger Sub, and immediately following which Legacy Momentus merged with and into the Second Merger Sub, with the Second Merger Sub as the surviving entity (the “Business Combination”). In connection with the closing of the Business Combination (“Closing”), the Company changed its name from Stable Road Acquisition Corp. to Momentus Inc., and Legacy Momentus changed its name to Momentus Space, LLC. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Business Combination was accounted for as a reverse recapitalization under ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with SRAC and its two wholly-owned subsidiaries. The Company received gross proceeds of $247.3 million upon the closing of the Business Combination. Public and private warrants of SRAC were assumed by the Company as a result of the Business Combination.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated interim financial statements have been prepared assuming that the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these consolidated interim financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. The Company’s ability to continue as a going concern is dependent on the Company’s ability to successfully raise capital to fund its business operations and execute on its business plan. To date, the Company remains heavily focused on growth and continued </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development of its proprietary technology, and, as a result, it has not generated sufficient revenues to provide cash flows that enable the Company to finance its operations internally and the Company’s financial position and operating results raise substantial doubt about the Company’s ability to continue as a going concern. This is reflected by the Company’s incurred net loss of $8.3 million for the three months ended March 31, 2024, and accumulated deficit of $381.4 million as of March 31, 2024. Additionally, the Company used net cash of $5.3 million to fund its operating activities for the three months ended March 31, 2024, and had cash and cash equivalents of $1.7 million as of March 31, 2024. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of ASC Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date these consolidated interim financial statements are issued. This evaluation does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented or are not within control of the Company as of the date the consolidated interim financial statements are issued. When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated interim financial statements are issued.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the preparation of the consolidated interim financial statements for the three months ended March 31, 2024, management conducted an evaluation and concluded that there were conditions and events, considered in the aggregate, which raised substantial doubt as to the Company’s ability to continue as a going concern within twelve months after the date of the issuance of such consolidated interim financial statements. The Company believes that its current level of cash and cash equivalents are not sufficient to fund its regular operations, scaling of commercial production, and maintain its existing services and products. These conditions raise substantial doubt regarding its ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated interim financial statements. In order to proceed with the Company’s business plan and operating strategy, the Company will need to raise substantial additional capital to fund its operations. Until such time, if ever, the Company can generate revenues sufficient to achieve profitability, the Company expects to finance its operations through equity or debt financings, which may not be available to the Company on the timing needed or on terms that the Company deems to be favorable. In an effort to alleviate these conditions, the Company continues to seek and evaluate all opportunities to access additional capital through any available means.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these uncertainties, and notwithstanding management’s plans and efforts to date, there is substantial doubt about the Company’s ability to continue as a going concern. If the Company is unable to raise substantial additional capital in the near term, or win new business, the Company's operations and business plan will need to be scaled back or halted altogether. Additionally, if the Company is able to raise additional capital but that capital is insufficient to provide a bridge to full commercial production at a profit, the Company's operations could be severely curtailed or cease entirely and the Company may not realize any significant value from its assets.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated interim financial statements have been prepared on a going concern basis of accounting. The accompanying consolidated interim financial statements do not reflect any adjustments that might result if the Company is unable to continue as a going concern.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Reverse Stock Split</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective August 22, 2023, the Company’s stockholders approved a 1-for-50 reverse stock split of the Company’s Class A common stock. As a result of the reverse stock split, every 50 shares of Class A common stock issued and outstanding on August 22, 2023, were automatically combined into one share of Class A common stock. Any fractional shares resulting from the reverse stock split were rounded up to the next nearest whole share of Class A common stock. The reverse stock split did not affect the stated par value of the Class A common stock nor did it change the total number of the Company’s authorized shares of Class A common stock. Both the Company’s Class B common stock and the Company’s preferred stock were not affected by the reverse stock split.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also on the effective date of the reverse stock split, all options, warrants and other convertible securities of the Company outstanding immediately prior to the reverse stock split were adjusted by dividing the number of shares of </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class A common stock into which the options, warrants and other convertible securities are exercisable or convertible by 50 and multiplying the exercise or conversion price thereof by 50, all in accordance with the terms of the plans, agreements or arrangements governing such options, warrants and other convertible securities and subject to rounding to the nearest whole share. Such proportional adjustments were also made to the number of shares and restricted stock units issued and issuable under the Company’s equity compensation plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has retroactively adjusted all periods presented for the effects of the stock split. See Note 9 for additional information.</span></div>
CY2024Q1	mnts	Number Of Spacecraft Missions NumberOfSpacecraftMissions	4	mission
CY2024Q1	mnts	Number Of Customer Satellites Deployed In Orbit NumberOfCustomerSatellitesDeployedInOrbit	17	satellite
CY2024Q1	mnts	Number Of Spacecraft Missions In Orbit NumberOfSpacecraftMissionsInOrbit	3	mission
CY2024Q1	mnts	Number Of Spacecraft Missions In Orbit NumberOfSpacecraftMissionsInOrbit	3	mission
CY2024Q1	mnts	Number Of Spacecraft Missions In Orbit NumberOfSpacecraftMissionsInOrbit	3	mission
CY2021Q3	mnts	Reverse Recapitalization Proceeds Received From Shareholders ReverseRecapitalizationProceedsReceivedFromShareholders	247300000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-8300000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-381400000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5300000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1700000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated interim financial statements and accompanying notes. Management bases its estimates on historical experience and on various other factors it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Accordingly, actual results could differ from those estimates. Significant estimates inherent in the preparation of the consolidated interim financial statements include, but are not limited to, the timing of revenue recognition, accounting for useful lives of property, machinery and equipment, net intangible assets, net accrued liabilities, leases, income taxes including deferred tax assets and liabilities, impairment valuation, stock-based compensation, warrant liabilities, and litigation contingencies.</span></div>
CY2024Q1	mnts	Deferred Fulfillment And Prepaid Launch Costs DeferredFulfillmentAndPrepaidLaunchCosts	400000	usd
CY2023Q4	mnts	Deferred Fulfillment And Prepaid Launch Costs DeferredFulfillmentAndPrepaidLaunchCosts	1700000	usd
CY2024Q1	us-gaap	Contract With Customer Asset Cumulative Catch Up Adjustment To Revenue Modification Of Contract ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract	500000	usd
CY2023Q1	us-gaap	Contract With Customer Asset Cumulative Catch Up Adjustment To Revenue Modification Of Contract ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract	0	usd
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1100000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1000000.0	usd
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	600000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1000000.0	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	500000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	500000	usd
CY2023	mnts	Contract With Customer Liability Revenue Recognized Excluding Opening Balance ContractWithCustomerLiabilityRevenueRecognizedExcludingOpeningBalance	35000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	513000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22000	usd
CY2024Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q1	mnts	Sale Of Stock Payment Of Liability SaleOfStockPaymentOfLiability	10000000	usd
CY2024Q1	mnts	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Other Comprehensive Income Extensible List Not Disclosed Flag FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfOtherComprehensiveIncomeExtensibleListNotDisclosedFlag	Change in Fair Value
CY2024Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2023Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2023Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	0	usd
CY2024Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	0	usd
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and cash equivalents in banks that management believes are creditworthy, however deposits may exceed federally insured limits.</span></div>
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	500000	usd
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2024Q1	mnts	Prepaid Launch Costs Current PrepaidLaunchCostsCurrent	0	usd
CY2023Q4	mnts	Prepaid Launch Costs Current PrepaidLaunchCostsCurrent	1260000	usd
CY2024Q1	mnts	Prepaid Research And Development Expense Current PrepaidResearchAndDevelopmentExpenseCurrent	2377000	usd
CY2023Q4	mnts	Prepaid Research And Development Expense Current PrepaidResearchAndDevelopmentExpenseCurrent	2415000	usd
CY2024Q1	mnts	Prepaid Insurance And Other Assets Current PrepaidInsuranceAndOtherAssetsCurrent	4847000	usd
CY2023Q4	mnts	Prepaid Insurance And Other Assets Current PrepaidInsuranceAndOtherAssetsCurrent	4838000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7224000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8513000	usd
CY2024Q1	mnts	Prepaid Launch Costs Noncurrent PrepaidLaunchCostsNoncurrent	400000	usd
CY2023Q4	mnts	Prepaid Launch Costs Noncurrent PrepaidLaunchCostsNoncurrent	400000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5815000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5815000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2770000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2563000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3045000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3252000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	200000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	200000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	540000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	193000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	347000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	519000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	177000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	341000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	46000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	61000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	61000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	61000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	52000	usd
CY2024Q1	mnts	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	66000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	347000	usd
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	10500000	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	368000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	368000	usd
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	150000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	122000	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	518000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	490000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M24D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.056
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1185000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1627000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1674000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1729000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	297000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6512000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	691000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	5821000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3679000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3811000	usd
CY2024Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	81000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	392000	usd
CY2024Q1	mnts	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	266000	usd
CY2023Q4	mnts	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	323000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	431000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	228000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4458000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4754000	usd
CY2023Q3	mnts	Common And Preferred Stock Shares Authorized CommonAndPreferredStockSharesAuthorized	274312500	shares
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.74
CY2024Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	4000000	usd
CY2024Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	500000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3500000	usd
CY2024Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.96
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.74
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.96
CY2024Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	4000000.0	usd
CY2024Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	400000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3600000	usd
CY2024Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2021Q2	mnts	Reverse Recapitalization Percentage Of Voting Interests Acquired ReverseRecapitalizationPercentageOfVotingInterestsAcquired	1
CY2021Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	10000000.0	usd
CY2021Q2	mnts	Proceeds From Sale Of Business And Other Capital Raising Transactions Minimum ProceedsFromSaleOfBusinessAndOtherCapitalRaisingTransactionsMinimum	250000000.0	usd
CY2023Q1	mnts	Reverse Recapitalization Proceeds Received From Shareholders ReverseRecapitalizationProceedsReceivedFromShareholders	247300000	usd
CY2023Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	10000000	usd
CY2023Q1	mnts	Sale Of Stock Payment Of Liability SaleOfStockPaymentOfLiability	10000000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	23912	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	68.39
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	830	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.13
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	23082	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	70.77
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M24D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	19213	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	59.48
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M6D
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	23082	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	70.77
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y4M24D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1443000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1720000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1443000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1720000	usd
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14823062	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	822825	shares
CY2024Q1	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On First Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary	3097000	usd
CY2024Q1	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On Second Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary	2975000	usd
CY2024Q1	us-gaap	Unrecorded Unconditional Purchase Obligation Balance Sheet Amount UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount	6072000	usd
CY2021Q2	mnts	Reverse Recapitalization Percentage Of Voting Interests Acquired ReverseRecapitalizationPercentageOfVotingInterestsAcquired	1
CY2021Q2	mnts	Reverse Recapitalization Payments To Co Founders ReverseRecapitalizationPaymentsToCoFounders	40000000	usd
CY2023Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	10000000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	10000000	usd
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	376234000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18739000	usd

Files In Submission

Name	View Source	Status
mnts-20240331_htm.xml	Edgar Link	completed
mnts-20240331_cal.xml	Edgar Link	unprocessable
mnts-20240331_cal.xml	Edgar Link	unprocessable
0001781162-24-000009-index-headers.html	Edgar Link	pending
0001781162-24-000009-index.html	Edgar Link	pending
0001781162-24-000009.txt	Edgar Link	pending
0001781162-24-000009-xbrl.zip	Edgar Link	pending
a20240331-ex311xceo.htm	Edgar Link	pending
a20240331-ex312xcfo.htm	Edgar Link	pending
a20240331-ex321xceo.htm	Edgar Link	pending
a20240331-ex322xcfo.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mnts-20240331.htm	Edgar Link	pending
mnts-20240331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mnts-20240331_def.xml	Edgar Link	unprocessable
mnts-20240331_lab.xml	Edgar Link	unprocessable
mnts-20240331_pre.xml	Edgar Link	unprocessable
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
0001781162-24-000009-index-headers.html	Edgar Link	pending
0001781162-24-000009-index.html	Edgar Link	pending
0001781162-24-000009.txt	Edgar Link	pending
0001781162-24-000009-xbrl.zip	Edgar Link	pending
a20240331-ex311xceo.htm	Edgar Link	pending
a20240331-ex312xcfo.htm	Edgar Link	pending
a20240331-ex321xceo.htm	Edgar Link	pending
a20240331-ex322xcfo.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mnts-20240331.htm	Edgar Link	pending
mnts-20240331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mnts-20240331_def.xml	Edgar Link	unprocessable
mnts-20240331_pre.xml	Edgar Link	unprocessable
mnts-20240331_lab.xml	Edgar Link	unprocessable
mnts-20240331_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MNTS
Momentus Inc. Stock $mnts

2024 Q1 Form 10-Q Financial Statement

#000178116224000009 Filed on October 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MNTS Momentus Inc. Stock $mnts

2024 Q1 Form 10-Q Financial Statement

#000178116224000009 Filed on October 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MNTS
Momentus Inc. Stock $mnts